The
coronavirus disease 2019 (COVID-19) pandemic continues to cause significant morbidity and mortality worldwide. Since a large portion of the world's population is currently unvaccinated or incompletely vaccinated and has limited access to approved treatments against
COVID-19, there is an urgent need to continue research on treatment options, especially those at low cost and which are immediately available to patients, particularly in low- and middle-income countries. Prior in vitro and observational studies have shown that
fluoxetine, possibly through its inhibitory effect on the
acid sphingomyelinase/
ceramide system, could be a promising
antiviral and anti-inflammatory treatment against
COVID-19. In this report, we evaluated the potential
antiviral and anti-inflammatory activities of
fluoxetine in a K18-hACE2 mouse model of
SARS-CoV-2 infection, and against variants of concern in vitro, i.e., SARS-CoV-2 ancestral strain, Alpha B.1.1.7, Gamma P1, Delta B1.617 and Omicron BA.5.
Fluoxetine, administrated after
SARS-CoV-2 infection, significantly reduced lung tissue viral titres and expression of several inflammatory markers (i.e., IL-6, TNFα, CCL2 and CXCL10). It also inhibited the replication of all variants of concern in vitro. A modulation of the
ceramide system in the lung tissues, as reflected by the increase in the ratio HexCer 16:0/Cer 16:0 in
fluoxetine-treated mice, may contribute to explain these effects. Our findings demonstrate the
antiviral and anti-inflammatory properties of
fluoxetine in a K18-hACE2 mouse model of
SARS-CoV-2 infection, and its in vitro
antiviral activity against variants of concern, establishing
fluoxetine as a very promising candidate for the prevention and treatment of
SARS-CoV-2 infection and disease pathogenesis.